We are live on ! Find out more
VTAE

VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE

Delisted

VTAE was delisted on the 24th of October, 2016.

Back to rankings

78 hedge funds and large institutions have $137M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 19

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

3% more funds holding

Funds holding: 76 → 78 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

52% less capital invested

Capital invested by funds: $284M → $137M (-$148M)

Holders
78
Holders Change
+2
Holders Change %
+2.63%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
18
Increased
32
Reduced
19
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$11.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.1M
4
DCM
DAFNA Capital Management
California
+$5.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.82M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.8M
3
DCM
Driehaus Capital Management
Illinois
-$4.4M
4
PA
Perceptive Advisors
New York
-$3.62M
5
Millennium Management
Millennium Management
New York
-$3.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
26
Highbridge Capital Management
New York
$718K +$985K +108,314 New
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$714K +$311K +34,144 +46%
GTC
28
Ghost Tree Capital
New York
$671K -$1.58M -173,812 -63%
OAM
29
Oxford Asset Management
United Kingdom
$648K +$889K +97,782 New
FSA
30
Franklin Street Advisors
North Carolina
$555K +$306K +33,700 +67%
Morgan Stanley
31
Morgan Stanley
New York
$475K +$512K +56,262 +366%
ARTA
32
A.R.T. Advisors
New York
$451K -$90K -9,900 -13%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$333K – – –
Goldman Sachs
34
Goldman Sachs
New York
$328K +$450K +49,444 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$323K +$61.9K +6,804 +16%
BIM
36
BlackRock Investment Management
Delaware
$310K +$8.24K +906 +2%
Invesco
37
Invesco
Georgia
$308K -$567K -62,340 -57%
TCIM
38
TIAA CREF Investment Management
New York
$256K -$62.1K -6,829 -15%
NFA
39
Nationwide Fund Advisors
Ohio
$255K -$13.6K -1,500 -4%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$245K -$1.51M -166,536 -82%
Jane Street
41
Jane Street
New York
$234K +$320K +35,224 New
GAMA
42
Graticule Asia Macro Advisors
New York
$224K -$54.8K -6,023 -15%
Charles Schwab
43
Charles Schwab
California
$221K +$5.57K +612 +2%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$189K +$35.4K +3,887 +16%
HLA
45
Hamilton Lane Advisors
Pennsylvania
$183K – – –
EMG
46
Ellington Management Group
Connecticut
$165K +$226K +24,900 New
CS
47
Credit Suisse
Switzerland
$164K +$225K +24,756 New
AA
48
ALPS Advisors
Colorado
$163K -$38.3K -4,215 -15%
QSS
49
Quantitative Systematic Strategies
Florida
$157K +$66.2K +7,282 +43%
Tudor Investment Corp
50
Tudor Investment Corp
Connecticut
$155K +$213K +23,393 New
1
2
3 4

VTAE Hedge Fund Activity: Q1 2016 in Review

78 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2016, worth a combined $137M — down 52% from $284M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VTAE positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 19 trimmed.

The largest buyer was RA Capital Management, adding an estimated $11.4M. The largest seller was OrbiMed, exiting entirely with an estimated $8.82M sold.

  • 78 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2016, up from 76 in Q4 2015.
  • Funds reported $137M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2016, down 52% quarter-over-quarter.
  • 18 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2016 and 16 closed out, a net change of +2 holders.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2016 was RA Capital Management, an estimated $11.4M added.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2016 was OrbiMed, an estimated $8.82M sold.

Based on aggregated 13F filings for Q1 2016.